SG Americas Securities LLC Raises Holdings in Orthofix Medical Inc. (NASDAQ:OFIX)

SG Americas Securities LLC raised its holdings in shares of Orthofix Medical Inc. (NASDAQ:OFIX) by 24.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,279 shares of the medical device company’s stock after purchasing an additional 4,162 shares during the period. SG Americas Securities LLC owned 0.06% of Orthofix Medical worth $372,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in OFIX. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Orthofix Medical by 5.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,994 shares of the medical device company’s stock valued at $156,000 after purchasing an additional 559 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in Orthofix Medical during the third quarter valued at about $216,000. Quest Partners LLC raised its holdings in Orthofix Medical by 187.1% during the third quarter. Quest Partners LLC now owns 13,908 shares of the medical device company’s stock valued at $217,000 after acquiring an additional 9,063 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Orthofix Medical in the third quarter worth about $270,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Orthofix Medical in the third quarter worth about $312,000. Institutional investors own 89.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. StockNews.com upgraded Orthofix Medical from a “hold” rating to a “buy” rating in a research report on Friday. Roth Mkm reiterated a “buy” rating and issued a $22.00 price target (up previously from $20.00) on shares of Orthofix Medical in a report on Friday, November 8th. Stifel Nicolaus raised shares of Orthofix Medical from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $18.00 to $24.00 in a research note on Friday, November 8th. Finally, Canaccord Genuity Group initiated coverage on shares of Orthofix Medical in a research note on Wednesday, January 22nd. They issued a “buy” rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.33.

Orthofix Medical Trading Down 0.7 %

Shares of Orthofix Medical stock opened at $18.20 on Tuesday. The firm has a market capitalization of $695.49 million, a PE ratio of -5.81 and a beta of 1.10. Orthofix Medical Inc. has a twelve month low of $12.08 and a twelve month high of $20.73. The firm’s 50-day moving average price is $18.05 and its 200 day moving average price is $17.11. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25.

Orthofix Medical (NASDAQ:OFIX) last released its quarterly earnings data on Thursday, November 7th. The medical device company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.57). The business had revenue of $196.61 million during the quarter, compared to analyst estimates of $196.60 million. Orthofix Medical had a negative net margin of 15.18% and a negative return on equity of 21.25%. During the same quarter in the previous year, the company posted ($0.77) EPS. On average, sell-side analysts predict that Orthofix Medical Inc. will post -2.81 EPS for the current fiscal year.

Insider Buying and Selling at Orthofix Medical

In related news, CEO Massimo Calafiore sold 10,078 shares of Orthofix Medical stock in a transaction on Friday, January 10th. The shares were sold at an average price of $16.83, for a total transaction of $169,612.74. Following the sale, the chief executive officer now directly owns 133,354 shares in the company, valued at $2,244,347.82. This trade represents a 7.03 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Julie Andrews sold 4,655 shares of Orthofix Medical stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $17.89, for a total transaction of $83,277.95. Following the completion of the transaction, the chief financial officer now owns 28,312 shares in the company, valued at approximately $506,501.68. This represents a 14.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,675 shares of company stock valued at $423,238 in the last 90 days. Company insiders own 2.60% of the company’s stock.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.